Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 28;14(13):3155.
doi: 10.3390/cancers14133155.

The Benefits of Radical Treatments with Synchronous Splenectomy for Patients with Hepatocellular Carcinoma and Portal Hypertension

Qikun Zhang  1 , Qi Li  2 , Fuchao Shang  3 , Guangming Li  1 , Menglong Wang  1
Affiliations

The Benefits of Radical Treatments with Synchronous Splenectomy for Patients with Hepatocellular Carcinoma and Portal Hypertension

Qikun Zhang et al. Cancers (Basel). .

Abstract

Background: The survival benefits of radical treatment (resection or radiofrequency ablation) combined with splenectomy for primary hepatocellular carcinoma (HCC) in patients with liver-cirrhosis-associated portal hypertension (PH) remain to be clarified. Methods: 96 patients undertaking HCC radical treatment combined with splenectomy (HS group) were retrospectively analyzed, 48 of whom belonged to HCC stage T1 (HSS group). Another 42 patients at stage T1 with PH who received hepatectomy (or radiofrequency ablation) alone (HA group) during the same period served as the control group. Recurrence-free survival (RFS) and overall survival (OS) were compared at each time point between the HSS and HA group. The risk factors affecting early RFS and OS were confirmed through COX multivariate analysis. Results: The median RFS was 22.3 months and the mean median OS was 46 months in the HS group. As such, 1-year, 2-year, 3-year, and 5-year RFS rates in the HSS and HA group were 95% and 81% (p = 0.041), 81% and 67% (p = 0.05), 64% and 62% (p = 1.00), and 29% and 45% (p = 0.10), respectively. Further, 1-year, 3-year, and 5-year OS rates in the HSS and HA group were 98% and 98% (p = 1.00), 79% and 88% (p = 0.50), and 60% and 64% (p = 0.61), respectively. Cox multivariate analysis showed that preoperative irregular anti-viral therapy, Child-Pugh grade B liver function, vascular invasion, and microvascular invasion (MVI) were independent risk factors for early postoperative RFS (within 2 years), and preoperative irregular anti-viral therapy and vascular invasion were independent risk factors for 5-year OS. Conclusions: Radical treatment of HCC combined with synchronous splenectomy, especially applicable to patients with Child-Pugh grade A liver function, can significantly improve early postoperative RFS in patients with stage T1 HCC and liver-cirrhosis-associated portal hypertension, but fail to improve OS.

Keywords: portal hypertension; primary hepatocellular carcinoma; radical treatment; synchronous splenectomy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The RFS and OS curves for different HCC stage in the HS group (A: RFS; B: OS).
Figure 2
Figure 2
The RFS curves at different time points compared between the HSS group and HA group (A: 1-year RFS; B: 2-year RFS; C: 3-year RFS; D: 5-year RFS).
Figure 3
Figure 3
The OS curves compared between the HSS group and HA group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cao W., Chen H.D., Yu Y.W., Li N., Chen W.Q. Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. Chin. Med. J. 2021;134:783–791. doi: 10.1097/CM9.0000000000001474. - DOI - PMC - PubMed
    1. De Lorenzo S., Tovoli F., Barbera M.A., Garuti F., Palloni A., Frega G., Garajova I., Rizzo A., Trevisani F., Brandi G. Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept. Sci. Rep. 2018;8:9997. doi: 10.1038/s41598-018-28337-6. - DOI - PMC - PubMed
    1. Rizzo A., Dadduzio V., Ricci A.D., Massari F., Di Federico A., Gadaleta-Caldarola G., Brandi G. Lenvatinib plus pembrolizumab: The next frontier for the treatment of hepatocellular carcinoma? Expert Opin. Investig. Drugs. 2022;31:371–378. doi: 10.1080/13543784.2021.1948532. - DOI - PubMed
    1. Rizzo A., Ricci A. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: How can they assist drug clinical trials? Expert Opin. Investig. Drugs. 2022;31:415–423. doi: 10.1080/13543784.2021.1972969. - DOI - PubMed
    1. National Health Care Commission Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition) Chin. Arch. Gen. Surg. 2022;16:81–96.